Vaccination against hepatitis viruses in Poland.
At present, two etiologic varieties of viral hepatitis (VH) can be directly vaccine-preventable: VH type A and VH type B. In addition, VH type D can be prevented indirectly through vaccination against VH-B. The first commercially available vaccine against VH-B appeared in 1981 and was human plasma-derived. After several years, it has generally been replaced by a recombinant type of vaccines. The obvious benefits of vaccination against VH-B prompted its introduction into the national immunization program in Poland in 1989. At that time, vaccination was offered free of charge to high-risk groups: newborns of HBsAg-carrier mothers, health-care workers, students: at medical schools, nursing schools, medical technology schools, and caretakers at institutions for mentally retarded persons. However, similarly to the experiences of other countries, observations in Poland indicated that such a targeted strategy fails to induce major epidemiological changes. In 1989 and in 1993, the incidence of VH-B per 100000 was 40.3 and 34.6, respectively. In addition, during these years, the incidence of V-B per 100000 children aged 0-4 years was 20.0 and 38.4, respectively. It has been decided that vaccination against VH-B will be obligatory for all newborns beginning from 1993. Due to financial constraints, it has been introduced in three phases, and since 1996, all newborns in Poland have been vaccinated. Already in 1993, three additional risk groups have been offered vaccination: patients with chronic diseases, patients awaiting planned surgery, and persons coming into close contact with acute VH-B or chronically HBV-infected individuals. In 1999, the incidence of VH-B per 100000 was 9.1/100000, and it may be assumed that vaccination helped to decrease the incidence of VH-B in Poland. The country experience with vaccination against VH-A is still limited. At present, it is recommended for children and adolescents and people dealing with food distribution, as well as for several other groups of people, such as travellers or long-term visitors (soldiers, missionaries, diplomats) to the endemic regions of the world. It has also been recommended in connection with natural disasters such as floods occurring in a large area of Poland in 1997.
Slusarczyk
J
J
Department of Sera and Vaccines Evaluation, National Institute of Hygiene, Chocimska st. 24, 00-791, Warsaw, Poland. jslusarczyk@pzh.gov.pl
D003428:Cross Infection / Q000209:etiology; D018563:Disease Notification; D006506:Hepatitis A / Q000453:epidemiology / Q000517:prevention & control; D022362:Hepatitis A Vaccines / Q000494:pharmacology; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000494:pharmacology; D006525:Hepatitis, Viral, Human / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D011044:Poland / Q000453:epidemiology; D012449:Safety; D014611:Vaccination / Q000639:trends; D014761:Viral Hepatitis Vaccines / Q000494:pharmacology*
D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines